Kelun-Biotech's HER2-Positive Breast Cancer Drug Study Results Published in JCO

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has published the results of its Phase III registrational study comparing its novel HER2-targeted antibody-drug conjugate trastuzumab botidotin against the competing treatment T-DM1. The study focused on patients with HER2-positive breast cancer.

The findings were presented in the Journal of Clinical Oncology (JCO), a leading peer-reviewed journal in the field. The publication in JCO validates the study's scientific merit and makes the results accessible to the broader medical community. The pharmaceutical company plans to leverage these findings for potential future treatment developments.

The study aimed to evaluate the efficacy and safety of trastuzumab botidotin compared to T-DM1 in patients whose breast cancer expresses the HER2 protein. HER2-positive breast cancer is a more aggressive form of the disease, and the search for more effective and tolerable treatment options is ongoing.

Kelun-Biotech's new drug candidate represents an advancement in antibody-drug conjugates. These types of drugs combine the targeting capabilities of antibodies with the cell-killing power of cytotoxic agents. The study's details and comparison to existing therapies provide valuable insights into the drug's potential clinical utility.